Cat. No.: HY-B1272A

Desipramine

15 Cited Publications

Based on 1 Customer Validation

Desipramine is a first-generation tricyclic antidepressant. Desipramine selectively binds to norepinephrine transporter and blocks neuronal norepinephrine reuptake. Desipramine activates MAPK signaling via ERK1/2, JNK, and p38, represses NF-κB and AP-1 activity, and induces apoptosis via ROS elevation, mitochondrial membrane potential reduction, and intracellular calcium increase. Desipramine also shows anyi-inflammatory activity, inhibiting TNF-α production. Desipramine can be used for the research of hepatocellular cancer, inflammation, and neurological diseases.

For research use only. We do not sell to patients.

CAS No.: 50-47-5
Formula: C₁₈H₂₂N₂
Molecular Weight:266.38

Storage:

Please store the product under the recommended conditions in the Certificate of Analysis.

Data Sheet (299 KB)

Desipramine Chemical Structure

CAS No.: 50-47-5

Size

Price

Stock

Quantity

Sample (0.1mg)

In-stock

(In Japan)

Apply Now

Get Quote Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability Get Quote Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability

Bulk Inquiry

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (15)
Purity & Documentation
References
Calculators
Help & FAQs
Bioz

Biological Activity

Description

IC₅₀ & Target^[1]

ERK1

ERK2

All Adrenergic Receptor Isoforms :

All ERK Isoforms :

All JNK Isoforms :

All p38 MAPK Isoforms :

All NF-κB Isoforms :

All AP-1 Isoforms :

All TNF Receptor Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
DG-75	IC₅₀	39.81 μM Compound: Desipramine	Reduction in cell viability of human DG75 cells after 24 hrs by Alamar blue viability assay Reduction in cell viability of human DG75 cells after 24 hrs by Alamar blue viability assay	[PMID: 23385211]
HEK293	IC₅₀	0.0524 μM Compound: desipramine	Inhibition of [3H]serotonin uptake in human SERT K490T mutant transfected HEK293 cells Inhibition of [3H]serotonin uptake in human SERT K490T mutant transfected HEK293 cells	[PMID: 17690258]
HEK293	IC₅₀	0.108 μM Compound: desipramine	Inhibition of [3H]serotonin uptake in human wild type SERT transfected HEK293 cells Inhibition of [3H]serotonin uptake in human wild type SERT transfected HEK293 cells	[PMID: 17690258]
HEK293	IC₅₀	17.7 μM Compound: desipramine	Inhibition of [3H]dopamine uptake in human DAT I390V mutant transfected HEK293 cells Inhibition of [3H]dopamine uptake in human DAT I390V mutant transfected HEK293 cells	[PMID: 17690258]
HEK293	IC₅₀	47.9 μM Compound: desipramine	Inhibition of [3H]dopamine uptake in human wild type DAT transfected HEK293 cells Inhibition of [3H]dopamine uptake in human wild type DAT transfected HEK293 cells	[PMID: 17690258]
HEK293	IC₅₀	50.5 μM Compound: desipramine	Inhibition of [3H]dopamine uptake in human DAT P387A mutant transfected HEK293 cells Inhibition of [3H]dopamine uptake in human DAT P387A mutant transfected HEK293 cells	[PMID: 17690258]
HEK293	IC₅₀	9.9 μM Compound: desipramine	Inhibition of [3H]dopamine uptake in human DAT F472L mutant transfected HEK293 cells Inhibition of [3H]dopamine uptake in human DAT F472L mutant transfected HEK293 cells	[PMID: 17690258]
HEK293	IC₅₀	0.0042 μM Compound: Desipramine	Inhibition of [3H]norepinephrine uptake at human NET expressed in HEK293 cells Inhibition of [3H]norepinephrine uptake at human NET expressed in HEK293 cells	[PMID: 17846138]
HEK293	IC₅₀	0.064 μM Compound: Desipramine	Inhibition of [3H]5HT uptake at human SERT expressed in HEK293 cells Inhibition of [3H]5HT uptake at human SERT expressed in HEK293 cells	[PMID: 17846138]
HEK293	IC₅₀	82 μM Compound: Desipramine	Inhibition of [3H]dopamine uptake at human DAT expressed in HEK293 cells Inhibition of [3H]dopamine uptake at human DAT expressed in HEK293 cells	[PMID: 17846138]
HEK293	IC₅₀	56.8 μM Compound: desipramine	Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium uptake at human OCT1 expressed in HEK293 cells by confocal microscopy Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium uptake at human OCT1 expressed in HEK293 cells by confocal microscopy	[PMID: 18788725]
HEK293	IC₅₀	1520 nM Compound: Desipramine	Inhibition of sodium current measured using whole-cell patch clamp experiments in HEK-293 cells stably transfected with hNaV1.5 cDNA Inhibition of sodium current measured using whole-cell patch clamp experiments in HEK-293 cells stably transfected with hNaV1.5 cDNA	[PMID: 21300721]
HEK293	IC₅₀	9.18 μM Compound: Desipramine	Inhibition of human OCT1 expressed in HEK293 cells assessed as decrease in uptake of ASP+ after 2 mins by fluorescence assay Inhibition of human OCT1 expressed in HEK293 cells assessed as decrease in uptake of ASP+ after 2 mins by fluorescence assay	[PMID: 28230985]
HeLa	IC₅₀	17.78 μM Compound: Desipramine	Reduction in cell viability of human HeLa cells after 24 hrs by Alamar blue viability assay Reduction in cell viability of human HeLa cells after 24 hrs by Alamar blue viability assay	[PMID: 23385211]
HRPE	IC₅₀	0.08 mM Compound: Desipramine	TP_TRANSPORTER: inhibition of TEA uptake in Octn1-HRPE cells TP_TRANSPORTER: inhibition of TEA uptake in Octn1-HRPE cells	[PMID: 10825452]
HRPE	IC₅₀	68 μM Compound: Desipramine	TP_TRANSPORTER: inhibition of MPP+ uptake (MPP+: 1 uM) in OCT3-expressing HRPE cells TP_TRANSPORTER: inhibition of MPP+ uptake (MPP+: 1 uM) in OCT3-expressing HRPE cells	[PMID: 9830022]
MDCK	IC₅₀	0.93 nM Compound: desipramine	Displacement of [125I]RTI-55 from human NET expressed in MDCK cell membrane Displacement of [125I]RTI-55 from human NET expressed in MDCK cell membrane	[PMID: 16989524]
MDCK	IC₅₀	3.9 nM Compound: desipramine	Inhibition of norepinephrine uptake at human NET expressed in MDCK cells Inhibition of norepinephrine uptake at human NET expressed in MDCK cells	[PMID: 18771916]
MDCK	IC₅₀	0.93 nM Compound: desipramine	Displacement of [125I]RTI55 from human recombinant norepinephrine transporter expressed in MDCK cells after 3 hrs Displacement of [125I]RTI55 from human recombinant norepinephrine transporter expressed in MDCK cells after 3 hrs	[PMID: 23403082]
MDCK	IC₅₀	1.5 nM Compound: Desipramine	Displacement of [3H]Nisoxetine from human recombinant NET over-expressed in dog MDCK cells Displacement of [3H]Nisoxetine from human recombinant NET over-expressed in dog MDCK cells	[PMID: 24012181]
Splenocyte	IC₅₀	22.9 μM Compound: Desipramine	Cytotoxicity against C57BL/6J mouse splenocytes after 72 hrs by alamar blue assay Cytotoxicity against C57BL/6J mouse splenocytes after 72 hrs by alamar blue assay	[PMID: 17846138]
Ventricular myocyte	IC₅₀	1709 nM Compound: Desipramine	Inhibition of calcium current (ICaL) measured using whole-cell patch clamp experiments in isolated guinea pig ventricular myocytes Inhibition of calcium current (ICaL) measured using whole-cell patch clamp experiments in isolated guinea pig ventricular myocytes	[PMID: 21300721]
Ventricular myocyte	IC₅₀	1.709 μM Compound: Desipramine	Inhibition of L-type calcium channel measured using whole-cell patch clamp in guinea pig ventricular myocytes Inhibition of L-type calcium channel measured using whole-cell patch clamp in guinea pig ventricular myocytes	[PMID: 22761000]
Ventricular myocyte	IC₅₀	11.7 μM Compound: Desipramine	Inhibition of L-type calcium channel measured using whole-cell patch clamp in rat ventricular myocytes Inhibition of L-type calcium channel measured using whole-cell patch clamp in rat ventricular myocytes	[PMID: 22761000]

In Vitro

Desipramine (3-500 µM; 24 h) reduces the viability of human hepatoma Hep3B cells in a dose-dependent manner^[1].
Desipramine (10-500 µM; 24 h) induces cytotoxicity in human hepatoma Hep3B cells in a dose-dependent manner, as measured by increased LDH release^[1].
Desipramine (3-100 µM; 24 h) increases intracellular ROS production in human hepatoma Hep3B cells in a dose-dependent manner^[1].
Desipramine (3-100 µM µM; 24 h) has its induced cell death in human hepatoma Hep3B cells abolished by the ROS scavenger NAC (HY-B0215) at concentrations up to 30 µM, and partially reduced at 100 µM after 24 h^[1].
Desipramine (3-100 µM; 24 h) reduces mitochondrial membrane potential in human hepatoma Hep3B cells in vitro in a dose-dependent manner^[1].
Desipramine (100 µM; 1-8 h) activates ERK1/2, JNK, and p38 MAPK signaling in human hepatoma Hep3B cells-^[1].
Desipramine (3-100 µM; 24 h) has its induced cell death in human hepatoma Hep3B cells abolished by inhibition of ERK1/2, p38, or JNK MAPK signaling^[1].
Desipramine (30-500 µM) increases intracellular calcium levels in human hepatoma Hep3B cells in a concentration-dependent manner, with increases occurring via both extracellular calcium influx and intracellular calcium release^[1].
Desipramine potently binds to the rat norepinephrine transporter with a K_i of 6.2 nM, showing 25-fold selectivity over the rat serotonin transporter (K_i = 158 nM) ^[3].
Desipramine (1 h) binds to the rat α₂D-adrenoceptor with a K_i of 3.4 μM^[3].
Desipramine potently binds to the human norepinephrine transporter with a K_i of 0.63 nM, has lower affinity for the human serotonin transporter (K_i = 22 nM), and lacks affinity for the human dopamine transporter (K_i > 10,000 nM)^[3].
Desipramine (0.01-10 μM; 20 h) dose-dependently inhibits LPS (HY-D1056)-induced TNF-α release from primary human monocytes^[4].
Desipramine (10 μM) reduces TNF-α-induced RANTES release and RANTES mRNA accumulation in A549 human lung epithelial cells^[4].
Desipramine (10 μM) represses TNF-α-induced NF-κB activity in A549 human lung epithelial cells^[4].
Desipramine (10 μM) reduces TPA (HY-18739)-induced AP-1 activity in A549 human lung epithelial cells^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[1]

Cell Line:

human hepatoma Hep3B cells
Concentration:

1 µM, 3 µM, 10 µM, 30 µM, 100 µM, 300 µM, 500 µM
Incubation Time:

24 h
Result:

Did not affect cell viability at 1 µM.
Reduced cell viability to 90.2% of control at 3 µM.
Reduced cell viability to 87.4% of control at 10 µM.
Reduced cell viability to 69.1% of control at 30 µM.
Reduced cell viability to 45.9% of control at 100 µM.
Reduced cell viability to 36.1% of control at 300 µM.
Reduced cell viability to 27.8% of control at 500 µM.
Caused statistically significant viability reductions at concentrations ≥3 µM compared to control.

Cell Cytotoxicity Assay^[1]

Cell Line:

human hepatoma Hep3B cells
Concentration:

10 µM, 30 µM, 100 µM, 300 µM, 500 µM
Incubation Time:

24 h
Result:

Increased LDH activity to 105.7% of control at 10 µM.
Increased LDH activity to 109.8% of control at 30 µM.
Increased LDH activity to 150.3% of control at 100 µM.
Increased LDH activity to 227.7% of control at 300 µM.
Increased LDH activity to 255.7% of control at 500 µM.
Caused statistically significant increases in LDH release at all tested concentrations compared to control.

Western Blot Analysis^[1]

Cell Line:

human hepatoma Hep3B cells
Concentration:

100 µM
Incubation Time:

1 h, 2 h, 4 h, 8 h
Result:

Increased phosphorylation of ERK1/2 to 185.2% of control at 1 h, 151.5% of control at 2 h, and 138.5% of control at 4 h.
Increased phosphorylation of p38 to 135.1% of control at 1 h and 116.4% of control at 2 h.
Increased phosphorylation of JNK to 118.9% of control at 1 h and 113.9% of control at 2 h.
Maintained unchanged total levels of ERK1/2, JNK, and p38 across all time points.
Caused statistically significant increases in MAPK phosphorylation at the specified time points compared to control.

In Vivo

Desipramine (5-20 mg/kg; i.p.; single dose, 30 minutes pre-LPS) dose-dependently inhibits LPS (HY-D1056)-induced serum TNF-α production and increases survival rate to 70% in a murine septic shock model^[4].
Desipramine (10 mg/kg; i.p.; daily; 8 days, 30 minutes pre-Ovalbumin nebulization) reduces lung inflammation by decreasing macrophage and lymphocyte counts in Ovalbumin (HY-W250978)-sensitized rats but does not attenuate bronchial hyperresponsiveness^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

LPS-induced BALB/c mice (5-week-old, 17-21 g)^[4]
Dosage:

5, 10, 20 mg/kg
Administration:

i.p.; single dose (preventive, 30 minutes pre-LPS)
Result:

Significantly inhibited LPS-induced serum TNF-α production.
Increased mouse survival rate to 70% with preventive 20 mg/kg treatment (vs 10% in saline controls).

Animal Model:

Ovalbumin-sensitized Brown Norway rats (10-week-old)^[4]
Dosage:

10 mg/kg
Administration:

i.p.; daily; 8 days (30 minutes pre-ovalbumin nebulization)
Result:

Did not reduce bronchial hyperresponsiveness to metacholine (measured by enhanced pause, Penh).
Reduced total number of inflammatory cells in bronchoalveolar lavages.
Decreased macrophage count by 52% compared to saline-treated sensitized rats.
Decreased lymphocyte count by 21% compared to saline-treated sensitized rats.
Did not reduce neutrophil or eosinophil counts compared to saline-treated sensitized rats.

Chemical Information

CAS No. 50-47-5
Molecular Weight 266.38
Formula C₁₈H₂₂N₂
SMILES

CNCCCN1C2=CC=CC=C2CCC3=CC=CC=C31
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Publications (15)

All Bio/Physico-chemical AssayCell Proliferation/Viability AssayWBCell Imaging/Staining

Sort by:

Journal Impact Factor

Cell

Unveiling conformation-selective regulation of the norepinephrine transporter. [Abstract]

2025 Nov 26;188(24):6861-6872.e14. PMID: 41138730
Acta Pharm Sin B

2026 Jan 27.
Sci Total Environ

Cadmium exacerbates liver injury by remodeling ceramide metabolism: Multiomics and laboratory evidence. [Abstract]

2024 May 1:923:171405. PMID: 38432385

Desipramine purchased from MedChemExpress. Usage Cited in: Sci Total Environ. 2024 May 1:923:171405. [Abstract]

Desipramine hydrochloride (Des; 0-50 μM; 24 h). Cell viability of BRL-3A cells after Des intervention was detected by CCK-8. Other groups were compared with 0 μM group.

Desipramine purchased from MedChemExpress. Usage Cited in: Sci Total Environ. 2024 May 1:923:171405. [Abstract]

Desipramine hydrochloride (Des; 12.5 μM; 24 h). The expression levels of apoptosis-related proteins in BRL-3A cells were detected by western blotting.

Desipramine purchased from MedChemExpress. Usage Cited in: Sci Total Environ. 2024 May 1:923:171405. [Abstract]

Desipramine hydrochloride (Des; 12.5 μM; 24 h). Hoechst/PI double staining: Hoechst/PI was used to double stain and observe them under fluorescence microscope (200×). Hoechst 33342 can stain the nucleus with blue fluorescence. PI can stain necrotic cells with red fluorescence.

Desipramine purchased from MedChemExpress. Usage Cited in: Sci Total Environ. 2024 May 1:923:171405. [Abstract]

Desipramine hydrochloride (Des; 12.5 μM; 24 h). The level of LDH in cell culture medium after 12.5 μM Des intervention and/or 20 μM Cadmium exposure for 24 h.
Br J Pharmacol

Serotonergic transmission plays differentiated roles in the rapid and sustained antidepressant-like effects of ketamine. [Abstract]

2024 Dec;181(23):4874-4889. PMID: 39238235
J Med Chem

Bioisostere-Driven Discovery of SePP: A Selenium-Containing Polypharmacological Agent Relevant to Fragile X Syndrome. [Abstract]

2026 Feb 10. PMID: 41666325
Neural Regen Res

Glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide dual receptor agonist DA-CH5 is superior to exendin-4 in protecting neurons in the 6-hydroxydopamine rat Parkinson model. [Abstract]

2021 Aug;16(8):1660-1670. PMID: 33433498
Pharmaceutics

Laminin Receptor-Mediated Nanoparticle Uptake by Tumor Cells: Interplay of Epigallocatechin Gallate and Magnetic Force at Nano-Bio Interface. [Abstract]

2022 Jul 22;14(8):1523. PMID: 35893779

Desipramine purchased from MedChemExpress. Usage Cited in: Pharmaceutics. 2022 Jul 22;14(8):1523. [Abstract]

Figure shows that 10 and 30 μM of Desipramine hydrochloride attenuated EGCG-induced enhancement of MNPcell by 8.9% and 39.3% in the Mag− group, respectively. In the Mag+ group, MNPcell was enhanced up to 6.6-fold by EGCG compared with the control group, which was minorly attenuated by 5.7% and 11.2% by Desipramine hydrochloride at 10 and 30 μM, respectively.
Glia

Potassium channel Kir 4.1 regulates oligodendrocyte differentiation via intracellular pH regulation. [Abstract]

2022 Nov;70(11):2093-2107. PMID: 35775976
Inflammation

Acid Sphingomyelinase and Acid β-Glucosidase 1 Exert Opposite Effects on Interleukin-1β-Induced Interleukin 6 Production in Rheumatoid Arthritis Fibroblast-Like Synoviocytes. [Abstract]

2021 Aug;44(4):1592-1606. PMID: 33665756
J Parkinson Dis

The Novel Dual GLP-1/GIP Receptor Agonist DA-CH5 Is Superior to Single GLP-1 Receptor Agonists in the MPTP Model of Parkinson's Disease. [Abstract]

2020;10(2):523-542. PMID: 31958096
Biochim Biophys Acta Mol Basis Dis

Involvement of Kir4.1 in pain insensitivity of the BTBR mouse model of autism spectrum disorder. [Abstract]

2023 Mar 28;1869(5):166700. PMID: 36990129
Neurotoxicology

Ropivacaine-induced seizures evoked pain sensitization in rats: Participation of 5-HT/5-HT3R. [Abstract]

2022 Dec:93:173-185. PMID: 36209936
Neuroscience

Acute Administration of Lactate Exerts Antidepressant-like Effect Through cAMP-dependent Protein Synthesis. [Abstract]

2024 Mar 26:542:11-20. PMID: 38336096
Parkinsons Dis

DA5-CH and Semaglutide Protect against Neurodegeneration and Reduce α-Synuclein Levels in the 6-OHDA Parkinson's Disease Rat Model. [Abstract]

2022 Nov 14:2022:1428817. PMID: 36419409
Research Square Print

2023 Feb 23.

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (299 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Yang DK, et al. Desipramine induces apoptosis in hepatocellular carcinoma cells. Oncol Rep. 2017;38(2):1029-1034. [Content Brief]

[2]. Kishore-Kumar R, et al. Desipramine relieves postherpetic neuralgia. Clin Pharmacol Ther. 1990;47(3):305-312. [Content Brief]

[3]. Deupree JD, et al. Pharmacological properties of the active metabolites of the antidepressants desipramine and citalopram. Eur J Pharmacol. 2007;576(1-3):55-60. [Content Brief]

[4]. Roumestan C, et al. Anti-inflammatory properties of desipramine and fluoxetine. Respir Res. 2007;8(1):35. Published 2007 May 3. [Content Brief]

Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass

Concentration

Volume

Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Desipramine

Publications Citing Use of MedChemExpress (MCE) Desipramine

All Adrenergic Receptor Isoforms

All ERK Isoforms

All JNK Isoforms

All p38 MAPK Isoforms

All NF-κB Isoforms

All AP-1 Isoforms

All TNF Receptor Isoforms